Jaypirca (pirtobrutinib) — CareFirst (Caremark)
Lymphoplasmacytic lymphoma
Initial criteria
- Requested as a single agent
- Previously treated disease
Reauthorization criteria
- No evidence of unacceptable toxicity or disease progression while on current regimen
Approval duration
12 months